Summary

KEY FINDINGS
The China surgical site infection control market is projected to record a CAGR of 6.15% during the projection period of 2024-2032. The market was valued at $325.85 million in 2023 and is expected to reach $559.05 million by 2032. The growth of the surgical site infection (SSI) control market in China is primarily driven by the high prevalence of SSIs, increasing awareness about infection control, and the emphasis on enhancing healthcare efficiency and patient safety. With a growing number of surgical procedures and a rising focus on preventing hospital-acquired infections, the market is expanding as healthcare providers adopt comprehensive infection control strategies to mitigate risks and improve patient outcomes.
MARKET INSIGHTS
Surgical site infections are a common type of hospital-acquired infection (HAI) that occur after surgical procedures, specifically affecting the area around the surgical incision. In China, the prevalence of SSIs is notably high, and several studies have aimed to quantify infection rates. One comprehensive study reported an overall SSI incidence of approximately 4.7% across various surgical departments, including internal medicine, oncology, hematology, neurology, and obstetrics. In this study, SSIs accounted for about 42% of all nosocomial infections.
Other independent studies highlighted particularly high incidence rates in specific procedures such as laryngectomy (21.1%), general surgery (18.8%), thoracic surgery (13.9%), and bone surgery (11.2%). Conversely, lower rates were observed in pancreatic surgery (7.1%), neurosurgery (3.0%), and Caesarean sections (0.7%). In these cases, the most common pathogens identified were Staphylococcus aureus and Pseudomonas aeruginosa.
The high prevalence of SSIs presents a significant burden on the healthcare system, as these infections lead to prolonged hospital stays and additional treatments. This not only affects patient recovery and satisfaction but also results in increased healthcare costs. As a result, there is a growing emphasis on implementing strategies and interventions aimed at reducing SSI rates.
These efforts, which include enhanced infection surveillance, adherence to surgical protocols, and improved sterilization techniques, have the potential to deliver substantial cost savings and boost overall healthcare efficiency. Such factors are expected to drive the growth of the SSI control market in China over the forecast period as hospitals and healthcare providers invest more in preventive measures to ensure patient safety and reduce the incidence of these infections.
SEGMENTATION ANALYSIS
The China surgical site infection control market segmentation includes procedure, type of infection, end-user, and product. The end-user segment is further classified into hospitals and ambulatory surgical centers. Ambulatory care refers to medical services provided in facilities where patients are not required to stay overnight. These facilities include hospital-based outpatient clinics, non-hospital-based clinics, physician offices, urgent care centers, ambulatory surgical centers (ASCs), public health clinics, imaging centers, oncology clinics, ambulatory behavioral health and substance abuse clinics, as well as physical therapy and rehabilitation centers.
Despite the convenience of ambulatory surgeries, healthcare-associated infections remain a common complication. However, most surgical-site infections are preventable due to stringent regulations that ensure ASCs adhere to safety standards comparable to those of hospitals.
This controlled environment, combined with advancements in technology, anesthesia, and minimally invasive surgical techniques, has significantly improved the safety of surgeries performed in ASCs. ASCs are also required to operate independently and cannot share physical space, even on a temporary basis, with hospital outpatient surgery departments or Medicare-participating independent diagnostic testing facilities (IDTFs).
COMPETITIVE INSIGHTS
Some of the top enterprises operating in the China surgical site infection control market include 3M Company, Ansell Ltd, Becton, Dickinson and Company (BD), etc.
Becton, Dickinson, and Company (BD) is a global leader in medical technology, specializing in the development, manufacturing, and distribution of medical devices, laboratory equipment, and diagnostic products. The company’s product portfolio includes syringes and pen needles, intravenous catheters, infusion pumps and disposables, automated medication dispensing systems, respiratory ventilation and diagnostic equipment, as well as diagnostic specimens.
BD also offers instruments designed to detect a wide range of infectious diseases, healthcare-associated infections, cancers, and clinical research tools. Its products serve life science researchers, healthcare institutions, clinical laboratories, the pharmaceutical industry, and the general public. With a broad geographic presence, BD operates across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. The company is headquartered in New Jersey, USA.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.6. MAJOR MARKET FINDINGS
2.6.1. HIGH EMPHASIS ON ENVIRONMENTAL HYGIENE BOOSTS THE SSI CONTROL MARKET
2.6.2. DISPOSABLE AND SINGLE-USE PRODUCTS ARE SHAPING THE SURGICAL INFECTION CONTROL LANDSCAPE
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN GERIATRIC POPULATION
3.1.2. INCREASED INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
3.1.3. IMPLEMENTATION OF REGULATORY GUIDELINES FOR THE PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS
3.2. KEY RESTRAINTS
3.2.1. LACK OF AWARENESS ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS
3.2.2. SURGING MEDICAL WASTE DUE TO THE USE OF MEDICAL DISPOSABLE ITEMS
3.2.3. RISING USE OF OUTPATIENT TREATMENTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING RATE OF SURGICAL PROCEDURES
4.1.2. EXPANSION OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
4.1.3. ADVANCEMENTS IN TECHNOLOGY FOR PREVENTING SURGICAL SITE INFECTIONS
4.2. PESTLE ANALYSIS
4.2.1. POLITICAL
4.2.2. ECONOMICAL
4.2.3. SOCIAL
4.2.4. TECHNOLOGICAL
4.2.5. LEGAL
4.2.6. ENVIRONMENTAL
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTIONS
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. MARKET CONCENTRATION ANALYSIS
5. MARKET BY PROCEDURE
5.1. LAPAROSCOPY
5.2. ORTHOPEDIC SURGERY
5.3. CARDIOVASCULAR
5.4. OBSTETRICS AND GYNECOLOGY
5.5. WOUND CLOSURE
5.6. PLASTIC & RECONSTRUCTIVE SURGERY
5.7. THORACIC SURGERY
5.8. MICROVASCULAR
5.9. UROLOGY
5.10. NEUROSURGERY
5.11. OTHER PROCEDURES
6. MARKET BY TYPE OF INFECTION
6.1. SUPERFICIAL INCISIONAL SSI
6.2. DEEP INCISIONAL SSI
6.3. ORGAN OR SPACE SSI
7. MARKET BY END-USER
7.1. HOSPITALS
7.2. AMBULATORY SURGICAL CENTERS
8. MARKET BY PRODUCT
8.1. DISINFECTANTS
8.1.1. SKIN DISINFECTANTS
8.1.2. HAND DISINFECTANTS
8.2. MANUAL REPROCESSORS SOLUTIONS
8.3. SURGICAL DRAPES
8.4. SURGICAL GLOVES
8.5. SKIN PREPARATION SOLUTIONS
8.6. SURGICAL IRRIGATION
8.7. SURGICAL SCRUBS
8.8. HAIR CLIPPERS
8.9. MEDICAL NONWOVENS
8.10. OTHER PRODUCTS
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PARTNERSHIPS & AGREEMENTS
9.1.3. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. 3M COMPANY
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCTS
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. ANSELL LTD
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCTS
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. BECTON, DICKINSON AND COMPANY
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCTS
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. JOHNSON & JOHNSON
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCTS
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. KIMBERLY-CLARK
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCTS
9.2.5.3. STRENGTHS & CHALLENGES